<< Back to News

System Formulary Update
Gadolinium Based Contrast Agents

Situation:

The gadolinium based contrast agent standardization was approved by the System Pharmacy & Therapeutics Committee in May 2024.

Background:

The following medication was reviewed: gadoterate meglumine (Dotarem/Cariscan); gadopiclenol (Elcirem/Vueway); gadoxetate disodium (Eovist); gadobutrol (Gadavist); gadobenate dimeglumine (MultiHance); gadodiamide (Omniscan); gaboteridol (ProHance)

Assessment/Recommendations:

System P&T voted to include the following product from the UNC Health Medication Formulary:

• Gadoterate meglumine (Dotarem)
• Gadopiclenol (Elucirem)
  • New addition to formulary 
• Gadoxetate disodium (Eovist)
• Gadobutrol (Gadavist)
• Gadobenate Dimeglumine (MultiHance)
  • use restricted to patients undergoing CNS/brain perfusion studies  

System P&T voted to exclude the following product from the UNC Health Medication Formulary:

• Gadodiamide (Omniscan)
• Gadoteridol (ProHance)
• Gadopiclenol (Vueway)
  • Note the Elucirem branded gadopiclenol will be added to formulary; Vueway branded product excluded

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, July 16, 2024